v3.23.1
COMBINED AND CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net loss $ (73,164) $ (64,851)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,015 726
Stock-based compensation expense 10,652 6,901
Write-off of other assets - related party   984
Other 91 85
Changes in assets and liabilities:    
Accounts receivable (1,550) (379)
Unbilled receivables (363) (91)
Inventory (312) (2,667)
Prepaid expenses and other current assets (1,837) (666)
Due from related parties (34) 1,451
Other assets - related party   260
Prepaid inventory (281)  
Other long term assets (632) (1,201)
Accounts payable (1,570) 1,436
Deferred grant funding (1,891) 1,052
Deferred revenue 1,664 1,082
Due to related parties (1,981) 1,845
Accrued expenses and other current liabilities (2,146) 6,851
Net cash used in operating activities (72,339) (47,182)
Cash flows from investing activities:    
Purchases of property and equipment (585) (2,711)
Net cash used in investing activities (585) (2,711)
Cash flows from financing activities:    
Proceeds from exercise of stock options 7 1,497
Proceeds from issuance of Series D convertible preferred stock   30,468
Stock issuance costs related to Series D convertible preferred stock   (7)
Repayment of notes payable   (178)
Investment from 4Bionics, LLC   3,516
Net proceeds from equity infusion from the Business Combination   141,471
Net cash provided by financing activities 7 176,767
Net (decrease) increase in cash and cash equivalents and restricted cash (72,917) 126,874
Cash, cash equivalents and restricted cash, beginning of year 191,160 64,286
Cash, cash equivalents and restricted cash, end of year 118,243 191,160
Reconciliation of cash, cash equivalents, and restricted cash reported in the balance sheets    
Cash and cash equivalents 117,472 188,498
Restricted cash 771 2,662
Total cash, cash equivalents and restricted cash 118,243 191,160
Supplemental disclosure of cash flow information:    
Cash received from exchange of research and development tax credits 131 374
Supplemental disclosure of noncash information:    
Write-off of notes receivable $ 90  
Issuance of Class A Common Stock to a service provider in exchange for the service provided in connection with the Business Combination   $ 3,000